Asymchem Takes New Step on Application of Continuous Reaction
Asymchem has become a global leader in the pharmaceutical CDMO industry. Asymchem has been committed to the development and commercial application of green pharmaceutical technologies for many years.
Under the leadership of Dr. Hao Hong, Chairman and CEO of Asymchem, Asymchem Laboratories (Tianjin) Co., Ltd. (SHE: 002821.SZ; Asymchem) has become a global leader in the pharmaceutical CDMO industry. Asymchem has been committed to the development and commercial application of green pharmaceutical technologies for many years. Recently, the test of the EP (key intermediates of penem antibiotic) flow chemistry equipment has been completed and will be operational for commercial production. As Asymchem’s first validated cGMP flow process, it marks a new step of Asymchem on the application of continuous reactions!
The
pharmaceutical industry is now facing new challenges in controlling and
preventing environmental pollution as it is expanding. “Greening” of
pharmaceutical processes is adopted as a goal by many national
governments; “green chemistry” is vigorously integrated to the business
strategies of many pharmaceutical companies. Green chemistry represented
by continuous reactions and bio-enzyme catalysis is expected to be an
efficient way to increase production efficiency and reduce waste
generation, energy use, and production cost.
The
batch production is usually adopted for traditional drug synthesis, in
which large amount of solvents is used, with problems of low yield, high
energy consumption, and serious pollution. As a new alternative route,
continuous reaction has been applied through which materials being
processed are continuously in motion in the whole production process,
undergoing chemical reactions or subject to mechanical or heat
treatment; online monitoring appliance is also used to monitor and
evaluate the probability or impact of risks to avoid accidence.
Converting the traditional batch operation to continuous operation has
many advantages including, but not limited to higher safety,
environmental protection, more throughput in shorter time at less cost,
and accelerated drug launch.
Through
continued R&D investment over the past 20 years, Asymchem has
successfully applied the continuous reactions to commercial production
of the key intermediates and APIs of the third line penem antibiotics, second line
anti-HIV drugs, anti-cancer drugs and other innovative drugs. The
successful application of continuous reaction has become a powerful tool
to realize the large scale production in the pharmaceutical industry.
4-AA is a critical starting material for the synthesis of penem antibiotics and
is in high demand. Ozone, commonly used as oxidant in traditional
production process, is highly risky and the temperature and homogeneity
of product is hard to precisely control. The process of continuous
ozonolysish reaction developed by Asymchem is safer and more
environmentally friendly. The fluids and
ozone can be continuously injected to the device; waste gas and
products can be continuously discharged from the device; online
monitoring and PLC auto-control system is applied with multiple
interlock to ensure safety. The output of one set of equipment alone can
produce 40mt/year. The equipment has many prominent advantages
including full automatic control, space saving, higher degree of safety,
shorter life cycle, high yield and purity, less cost and energy use,
green.
Moreover,
Asymchem developed a new synthetic route for commercial EP production–
only 3 steps is needed the shortest route of synthesis. The EP flow
chemistry equipment for commercial production has completed the test and
will be verified soon. The equipment is equipped with continuous
immobilization reaction column and PFR, used respectively for continuous
cyclization reaction and continuous esterification reaction. The set of
equipment uses HPLC to monitor the drug quality and DCS system to
achieve precise automatic control. The equipment has advantages of space
saving, high productivity of >60mt/year/one set, less catalyst
and easy recycle. The large scale production of EP was realized through
combination of blocks and automatic control, an example of End-to-End
green production.
Asymchem
has received many awards and qualifications for the company’s
contribution in the R&D and application of continuous reaction
technology. Asymchem was awarded with “the Excellent Award for Chinese
Patented Invention”, “Special Award for Green Pharmaceutical Technology
in 2017/2018” and others. Asymchem was recognized as “State-certified
Enterprise Technology Center”, “National and Local Green Chemistry
Collaboration Laboratory”, “Tianjin Municipal Enterprise Key
Laboratories of Green Synthetic Technology”, as well as a member of “ACS
GCI Green Chemistry Roundtable”. Moreover, Asymchem has also
established the International Green Chemistry Collaboration Laboratory
with Professor K. Barry Sharpless, Nobel Prize winner in Chemistry,
Prof. Jin-Quan Yu, MacArthur Genius Award winner, and Prof. Phil Baran,
MacArthur Genius Award winner from Scripps Research Institute, with an
aim to promote the green pharmaceutical technology to the production of
innovative drugs and blockbuster drugs in major therapeutic areas.
Asymchem
will continue to invest resource and committed efforts to develop green
pharmaceutical technologies. The philosophy of “Green Chemistry Is the
Future” is at the forefront of everything Asymchem does in its mission
to promote the innovation and aid in the progress of the global
pharmaceutical industry.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance